8-K: BIOLASE Reports Second Quarter 2024 Results, Achieves 40% Gross Margin Amid Consumable Sales Growth

BIOLASE reported its second quarter 2024 financial results, highlighting a 40% gross margin and strong consumable revenue despite overall revenue challenges.

Summary

• BIOLASE announced its financial results for the second quarter of 2024, ending June 30th.
• The company achieved a gross margin of 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts.
• Consumable revenue was the second highest ever, with over 600 recurring subscriptions, translating to over $2 million in scheduled shipments over the next twelve months.
• Net revenue for the quarter was $11.6 million, compared to $14.3 million in the same quarter of 2023.
• U.S. laser revenue decreased to $3.6 million from $6.3 million year-over-year.
• U.S. consumables and other revenue decreased by 5% year-over-year.
• International laser revenue was $2.4 million, slightly down from $2.5 million year-over-year.
• International consumables and other revenue decreased by 12% year-over-year.
• Total operating expenses decreased by 22% year-over-year to $7.8 million.
• The operating loss improved by 17% year-over-year to $3.2 million.
• The company had approximately $5.3 million in cash and cash equivalents as of June 30, 2024.
• Net loss attributable to common stockholders was $2.8 million, or $0.08 per share, compared to a net loss of $14.2 million, or $26.14 per share, in the same quarter of 2023.
• Adjusted EBITDA was a loss of $2.5 million, or $0.08 per share, compared to an Adjusted EBITDA loss of $2.3 million, or $4.24 per share, in the same quarter of 2023.
• Full-year 2024 revenue is now expected to be similar to 2023, with a lower capital equipment revenue forecast for the second half of the year.
• The company expects a full-year 2024 Adjusted EBITDA loss between $6 million and $8 million, an improvement over the $12.8 million loss in 2023.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there are positive aspects like improved gross margin and reduced operating expenses, the overall revenue decline and continued losses temper the positive sentiment. The company's future outlook is also uncertain, with no expected revenue growth for the year.

Positives

• The gross margin increased to 40%, indicating improved profitability.
• Consumable sales are strong, with recurring subscriptions and scheduled shipments providing future revenue visibility.
• Operating expenses decreased significantly, contributing to a reduced operating loss.
• The net loss per share improved substantially year-over-year.
• The company is projecting an improved Adjusted EBITDA loss for the full year 2024 compared to 2023.

Negatives

• Net revenue decreased to $11.6 million from $14.3 million year-over-year.
• U.S. laser revenue decreased significantly to $3.6 million from $6.3 million year-over-year.
• Both U.S. and international consumable revenue decreased year-over-year.
• The company is still operating at a loss, with a net loss of $2.8 million for the quarter.
• Adjusted EBITDA remains negative, with a loss of $2.5 million for the quarter.
• Full-year 2024 revenue is expected to be similar to 2023, indicating no growth.

Risks

• The company is facing revenue challenges due to higher interest rates.
• There is uncertainty in the market, impacting the company's ability to forecast revenue.
• The company is experiencing a lower capital equipment revenue forecast for the second half of 2024.
• The company's ability to sustain growth is uncertain.
• There are competitive factors, including pricing pressures and new product introductions, that could impact the company.
• Customer acceptance of new product offerings and market changes are uncertain.
• The company faces risks associated with managing the growth of the business.
• There is substantial doubt regarding BIOLASE's ability to continue as a going concern.

Future Outlook

The company expects full-year 2024 revenue to be similar to 2023, with a lower capital equipment revenue forecast for the second half of the year. The company also expects a full-year 2024 Adjusted EBITDA loss between $6 million and $8 million.

Management Comments

• We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions, commented John Beaver, President and Chief Executive Officer of BIOLASE.
• This success translates to over $2 million in scheduled shipments over the next twelve months.
• Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year.
• Despite ongoing revenue challenges due to higher interest rates, I believe our performance shows that we are well-positioned for greater gains once our market returns to normal and dental practitioners have the purchasing power they have historically been accustomed to in the past.
• The positive response to the U.S. launch of our Waterlase iPlus Premier laser system last quarter underscores the strong interest in our industry-leading products and our commitment to innovation and customer satisfaction.

Industry Context

The dental laser market is competitive, with companies focusing on innovation and customer satisfaction. BIOLASE's results reflect the broader economic challenges impacting the dental industry, such as higher interest rates affecting capital equipment purchases. The company's focus on recurring consumable revenue is a common strategy in the medical device industry to build a stable revenue base.

Comparison to Industry Standards

• While BIOLASE's gross margin of 40% is a positive sign, it is important to compare this to other medical device companies in the dental space. Companies like Align Technology (ALGN) and Dentsply Sirona (XRAY) typically have higher gross margins, often in the 60-70% range, reflecting their scale and product mix.
• BIOLASE's revenue decline year-over-year is concerning, as many medical device companies have shown growth in recent periods. For example, companies like Intuitive Surgical (ISRG) have demonstrated consistent revenue growth, driven by increased adoption of their robotic surgery systems.
• The improvement in operating loss and Adjusted EBITDA is a positive trend for BIOLASE, but the company still needs to achieve profitability. Companies like Stryker (SYK) and Medtronic (MDT) are benchmarks for profitability in the medical device industry, with consistent positive earnings.
• BIOLASE's focus on consumable revenue is a good strategy, similar to companies like Danaher (DHR) that have a strong recurring revenue base from consumables and services. However, BIOLASE needs to scale this revenue stream to offset the decline in capital equipment sales.
• The company's cash position of $5.3 million is relatively low compared to larger competitors, which may limit its ability to invest in growth initiatives. Companies like Boston Scientific (BSX) have significantly larger cash reserves, providing them with more financial flexibility.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and continued losses, but encouraged by the improved gross margin and reduced operating expenses.
• Employees may be affected by the company's cost reduction efforts.
• Customers may benefit from the company's focus on innovation and customer satisfaction.
• Suppliers may be impacted by the company's financial performance.
• Creditors may be concerned about the company's financial position and ability to repay debts.

Key Dates

Keywords

dental lasers, BIOLASE, financial results, gross margin, consumable revenue, adjusted EBITDA, operating loss, net loss, laser systems, dental technology